


Introduction


- IDEXX Cancer Dx testing is a new commercially available blood-based test to screen for and diagnose canine lymphoma.
- It has excellent specificity for identifying lymphoid neoplasia but data on screening situations is limited.

Methods


IDEXX Cancer Dx testing was performed retrospectively on a banked, convenience sample of canine whole blood and serum submitted to IDEXX Reference Laboratories in North America.



Results



Proportion of Wellness Positives Diagnosed with Lymphoma*



Median Time to Lymphoma Diagnosis

96
Days
(21-221 days)

Outcomes for Wellness Positives*

- 7/17 (41%) were diagnosed with lymphoma (21-221 days post bloodwork).
- 3/17 (18%) died without a definitive diagnosis (45-327 days post bloodwork).
- 7/17 (41%) have not reached an endpoint (104-421 days post bloodwork); 3 of these have >1 year of follow-up without a diagnosis of lymphoma.

Discussion

- IDEXX Cancer Dx testing has the potential to identify lymphoma before clinical suspicions in dogs.
- Since this study used banked samples, Cancer Dx testing results did not influence the care that patients received.
- Preliminary data suggests a Cancer Dx testing positive result may precede diagnosis of lymphoma by up to 6-8 months.
- Close monitoring of apparently healthy patients with a positive Cancer Dx testing result for evidence of lymphoma is warranted.

Future Directions

A longitudinal prospective monitoring study evaluating the utility of IDEXX Cancer Dx testing in wellness care is underway.

Acknowledgements

IDEXX Discovery and Development Teams were instrumental in assay finalization and data collection for this dataset.

[References available on request](#)